Metrenperone

Metrenperone

SCHEMBL2109868

Cc1ccc2nc(C)c(CCN3CCC(C(=O)c4ccc(F)cc4)CC3)c(=O)n2c1

nearest known ligand 0.77

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 6/20 0.77
CYP2D6 P10635 4/20 0.77
SMN1; SMN2 Q16637 3/20 0.77
CYP3A4 P08684 3/20 0.77
MAPT P10636 3/20 0.77
TSHR P16473 3/20 0.77
KDM4E B2RXH2 3/20 0.77
MEN1 O00255 2/20 0.77
HTR1A P08908 2/20 0.77
PKM P14618 2/20 0.77
PMP22 Q01453 2/20 0.77
KMT2A Q03164 2/20 0.77
HPGD P15428 1/20 0.77
THPO P40225 1/20 0.77
HTR2A P28223 8/20 0.53
HTR7 P34969 5/20 0.53
HTR6 P50406 5/20 0.53
ALDH1A1 P00352 3/20 0.49
ADRA2A P08913 2/20 0.49
ADRA2B P18089 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6522324 0.92 HTR2C (0.76) HTR2CCYP2D6SMN1; SMN2CYP3A4MAPT
Pirenperone SCHEMBL467209 0.87 HTR2C (1.00) HTR2CCYP2D6SMN1; SMN2CYP3A4MAPT
Pirenperone SCHEMBL10965711 0.86 HTR2C (0.98) HTR2CCYP2D6SMN1; SMN2CYP3A4MAPT
Pirenperone SCHEMBL10970070 0.84 HTR2C (0.93) HTR2CCYP2D6SMN1; SMN2CYP3A4MAPT
Pirenperone SCHEMBL10967003 0.84 HTR2C (0.93) HTR2CCYP2D6SMN1; SMN2CYP3A4MAPT
SCHEMBL6527939 0.84 HTR2C (0.77) HTR2CCYP2D6SMN1; SMN2CYP3A4MAPT
SCHEMBL17532707 0.83 CYP2D6 (0.86) HTR2CCYP2D6SMN1; SMN2CYP3A4MAPT
SCHEMBL6518627 0.83 ACHE (0.54) HTR2CCYP2D6SMN1; SMN2CYP3A4MAPT
SCHEMBL6518635 0.83 ACHE (0.54) HTR2CCYP2D6SMN1; SMN2CYP3A4MAPT
SCHEMBL6518624 0.83 ACHE (0.54) HTR2CCYP2D6SMN1; SMN2CYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
EP-2252608-A1 METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS VM Discovery, Inc. (US) 2010-11-24 EP claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
WO-2009108798-A1 METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS VM DISCOVERY INC. (US) 2009-09-03 WO claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
EP-0268309-B1 Serotonin antagonists for treating wounds JANSSEN PHARMACEUTICA NV (BE) 1996-12-11 EP claimed
US-4874766-A TOPICALLY APPLYING SEROTONIN ANTAGONIST JANSSEN PHARMACEUTICA N.V. (BE) 1989-10-17 US claimed
US-20220047505-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2022-02-17 US disclosed
US-11191719-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2021-12-07 US disclosed
EP-3106166-B1 COMPOUNDS FOR TREATING PAIN SYNDROME AND OTHER DISORDERS VM THERAPEUTICS LLC (US) 2020-12-02 EP disclosed
EP-3106166-B1 COMPOUNDS FOR TREATING PAIN SYNDROME AND OTHER DISORDERS VM THERAPEUTICS LLC (US) 2020-12-02 EP disclosed
US-10471140-B2 Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition NOTTO DENKO CORPORATION (JP) 2019-11-12 US disclosed
US-4870060-A SOLUBILIZERS FOR DRUGS JANSSEN PHARMACEUTICA (BE) 1989-09-26 US disclosed
US-4837168-A QUALITATIVE, QUANTITATIVE ANALYSIS; VISUAL DETERMINATION JANSSEN PHARMACEUTICA N.V. (BE) 1989-06-06 US disclosed
EP-0317001-A1 A new universally applicable detection system based 0n ultra small colloidal metal particles JANSSEN PHARMACEUTICA N.V. (BE) 1989-05-24 EP disclosed
US-4764604-A Derivatives of gamma-cyclodextrin JANSSEN PHARMACEUTICA N.V. (BE) 1988-08-16 US disclosed
EP-0197571-A2 Novel derivatives of gamma-cyclodextrin JANSSEN PHARMACEUTICA N.V. (BE) 1986-10-15 EP disclosed